Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06655324 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
200
Enrollment target
9
Study locations

NCT06655324 is a Phase 1 study of Healthy that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 200 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06655324, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
9
Study locations

Study Summary

Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.

Conditions Studied

Healthy

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL V350A
  • BIOLOGICAL V350B

Study Locations (9)

Missouri

  • Alliance for Multispecialty Research, LLC ( Site 0008) - Kansas City
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016) - Springfield

Nebraska

  • Velocity Clinical Research Lincoln ( Site 0004) - Lincoln
  • Velocity Clinical Research, Omaha ( Site 0005) - Omaha

California

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0011) - Glendale

Florida

  • QPS-MRA, LLC ( Site 0012) - Miami

Ohio

  • Remington-Davis, Inc. ( Site 0017) - Columbus

Oklahoma

  • Lynn Health Science Institute ( Site 0010) - Oklahoma City

Tennessee

  • Alliance for Multispecialty Research, LLC ( Site 0009) - Knoxville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-12-05
Est. Completion 2028-07-17
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06655324

The ClinicalTrials.gov registry entry for NCT06655324 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06655324 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Missouri, Nebraska, California.

Frequently Asked Questions

What is clinical trial NCT06655324 about?

NCT06655324 is a clinical study titled "A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).". Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this s...

What is the current status of trial NCT06655324?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2024-12-05. Estimated completion is 2028-07-17.

What conditions does trial NCT06655324 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06655324?

The interventions under investigation include: Placebo (BIOLOGICAL), V350A (BIOLOGICAL), V350B (BIOLOGICAL).

Who is sponsoring clinical trial NCT06655324?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06655324 being conducted?

This trial has 9 study locations across California, Florida, Missouri, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.